Premium
Thrombopoietin and the TPO receptorduring platelet storage
Author(s) -
Xia Y.,
Li J.,
Bertino A.,
Kuter D.J.
Publication year - 2000
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.2000.40080976.x
Subject(s) - thrombopoietin , platelet , thrombopoiesis , chemistry , megakaryocyte , hematopoietic growth factor , endocrinology , receptor , medicine , andrology , haematopoiesis , biology , biochemistry , stem cell , microbiology and biotechnology
BACKGROUND: For most cells, the addition of a specific growth factor has improved cellular viability by preventing programmed cell death (apoptosis). To determine whether the platelet‐specific hematopoietic growth factor thrombopoietin (TPO) might improve platelet viability, endogenous TPO and the platelet TPO receptor were analyzed during storage, and the effect of recombinant TPO on platelet viability was assessed. STUDY DESIGN AND METHODS: During platelet storage, TPO stability was assessed by SDS‐PAGE, TPO receptor function was measured, and the platelet TPO receptor was characterized by a 125 I‐rHuTPO competitive‐binding assay. A recombinant TPO, pegylated recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF), was added to platelet concentrates during storage, and its effect on pH, LDH, and metabolic activity was determined. RESULTS: During storage, the molecular weight and concentration of endogenous TPO (125 ± 19 pg/mL) and exogenous TPO (5720 ± 140 pg/mL) were constant for 12 days; the number (33 ± 4), binding affinity (149 ± 33 pM), and function of the platelet TPO receptors were constant for 7 days. Metabolic activity measured with the MTT and MTS assays closely correlated with changes in the pH and LDH. The addition of PEG‐rHuMGDF did not alter the pH, LDH, or metabolic activity of platelets during storage, but it did increase by 65 percent the uptake of 35 S‐methionine into platelets. Finally, platelet concentrates obtained from donors treated with PEG‐rHuMGDF retained normal metabolic activity for 12 days, as compared with 5 to 6 days for normal platelet concentrates. CONCLUSIONS: TPO and its platelet receptor are present in normal amounts and have normal function during platelet storage. The addition of recombinant TPO increased platelet methionine transport but did not alter platelet viability during storage. Other means to prevent apoptosis during platelet storage should be considered, and the measurement of platelet metabolic activity by MTT and MTS assays may assist this effort.